Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 5/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026357 | 0.87 | ESR1 (1.00) | ESR1ESR2RORCSCN5ASCN9A | |
| SCHEMBL4029651 | 0.85 | ESR1 (0.77) | ESR1ESR2RORCNR1H2NR1H3 | |
| SCHEMBL4027587 | 0.83 | ESR1 (0.53) | ESR1ESR2RORCNR1H2NR1H3 | |
| SCHEMBL4035239 | 0.76 | ESR1 (0.80) | ESR1ESR2RORCNR1H2NR1H3 | |
| SCHEMBL4025242 | 0.75 | ESR1 (0.44) | ESR1RORCSCN5ASCN9A | |
| SCHEMBL4197102 | 0.75 | ESR1 (0.44) | ESR1RORCSCN5ASCN9A | |
| SCHEMBL4030678 | 0.74 | ESR1 (0.77) | ESR1ESR2RORCNR1H2NR1H3 | |
| SCHEMBL5397380 | 0.74 | ESR1 (0.56) | ESR1ESR2RORC | |
| SCHEMBL4026335 | 0.74 | ESR1 (0.75) | ESR1ESR2 | |
| SCHEMBL4035727 | 0.72 | ESR1 (0.57) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885ESR2 621/4885RORC 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.